Longeveron reported new Phase 2a CLEAR MIND data at AAIC 2026 showing laromestrocel reduced brain inflammation and identified biomarker changes supporting Phase 3 development in mild Alzheimer’s disease.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Longeveron Inc. has reported new analyses from its Phase 2a CLEAR MIND trial (NCT05233774) showing that its investigational cell therapy, laromestrocel (Lomecel-B®), reduced MRI markers of neuroinflammation in patients with mild Alzheimer’s disease (AD). The findings, presented in a poster titled “Laromestrocel Stabilizes Brain Inflammation in Key Alzheimer’s Disease Gray and White Matter Regions as Assessed Using Free Water MRI” at the 2026 Alzheimer’s Association International Conference (AAIC), provide additional evidence supporting the therapy’s anti-inflammatory mechanism of action and its continued clinical development.
Post-hoc Analysis Strengthens Phase 2a Findings
The new data come from a post-hoc exploratory analysis of the randomized Phase 2a CLEAR MIND study, which evaluated four treatment groups: placebo, a single 25 million-cell dose (25Mx1), four monthly 25 million-cell doses (25Mx4), and four monthly 100 million-cell doses (100Mx4). Investigators assessed changes in brain inflammation using free water magnetic resonance imaging (MRI), an emerging biomarker of neuroinflammation, alongside clinical outcomes and blood-based biomarkers.
The exploratory analysis found that patients receiving placebo experienced progressive increases in free water over 39 weeks in several Alzheimer’s disease-related white matter regions, including the fornix, sagittal stratum, and uncinate fasciculus. In contrast, patients treated with laromestrocel showed lower free water measurements than placebo across all treatment groups, with several comparisons approaching statistical significance. The anti-inflammatory effects were most pronounced in the hippocampus, temporal lobe, and other brain regions commonly affected by Alzheimer’s disease.
MRI and Biomarker Findings Support Disease-Modifying Potential
Reductions in free water correlated with increased brain volume, improved cognitive performance, and better quality-of-life outcomes, providing converging imaging and clinical evidence of laromestrocel’s biological activity.
Blood biomarker analyses performed using the NuLISA platform further supported these findings. Patients receiving four monthly 25 million-cell doses showed a significant reduction in neurogranin, a marker of neuronal injury, compared with placebo (p=0.023). Meanwhile, patients receiving a single 25 million-cell dose demonstrated significantly higher levels of interleukin-13 (IL-13), an anti-inflammatory cytokine involved in regulating microglial activation (p=0.043).
Together, the imaging and biomarker findings suggest that laromestrocel may slow disease-related neuroinflammation while preserving brain structure and supporting clinical function.
Why Targeting Neuroinflammation Matters
Neuroinflammation is increasingly recognized as a major contributor to Alzheimer’s disease progression, brain atrophy, and cognitive decline. Most approved Alzheimer’s therapies target amyloid pathology, but none has been established as directly reducing the chronic neuroinflammation that contributes to ongoing neuronal injury. The latest AAIC findings provide additional mechanistic evidence supporting laromestrocel as a regenerative cell therapy with anti-inflammatory, pro-vascular, and tissue repair properties.
Clinical Implication
Commenting on the findings, Joshua Hare, M.D., Co-founder, Chief Science Officer, and Executive Chairman of Longeveron, said the new analyses further validate laromestrocel’s therapeutic potential in mild Alzheimer’s disease by linking reduced brain inflammation with structural brain preservation and improved clinical outcomes. He added that the company is continuing partnership discussions to advance the program into late-stage clinical development.
Regulatory Status and Path Forward
The U.S. Food and Drug Administration (FDA) has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the treatment of mild Alzheimer’s disease. Longeveron also reported that it has aligned with the FDA on the design of a Phase 3 clinical trial, marking an important milestone toward late-stage development.
Earlier results from the Phase 2a CLEAR MIND trial were published in the peer-reviewed journal Nature Medicine in 2025, providing independent scientific support for the continued development of laromestrocel in Alzheimer’s disease.
What This Means for Patients
The AAIC 2026 findings add to growing evidence that targeting neuroinflammation could become an important strategy for slowing Alzheimer’s disease progression. If these results are confirmed in Phase 3 studies, laromestrocel could emerge as a novel disease-modifying therapy that helps reduce harmful brain inflammation, preserve brain structure, and maintain cognitive function alongside existing Alzheimer’s treatments.
References
About the Writer
Chikkula Pavan Kumar (LinkedIn), PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.